CHRONIC GRAFT VS. HOST DISEASE
Clinical trials for CHRONIC GRAFT VS. HOST DISEASE explained in plain language.
Never miss a new study
Get alerted when new CHRONIC GRAFT VS. HOST DISEASE trials appear
Sign up with your email to follow new studies for CHRONIC GRAFT VS. HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stem cell transplant patients with severe immune complication
Disease control Recruiting nowThis study tests a drug called ruxolitinib in Chinese patients aged 12 and older who have chronic graft-versus-host disease (cGvHD) that did not improve with steroids. cGvHD is a condition where donor immune cells attack the patient's body after a stem cell transplant. The goal i…
Matched conditions: CHRONIC GRAFT VS. HOST DISEASE
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental drug axatilimab made available for one patient with chronic GVHD
Disease control AVAILABLEThis program offers expanded access to the drug axatilimab for a single patient with chronic graft versus host disease (GVHD), a complication after a stem cell transplant. The patient receives intravenous doses every two weeks. Approval is needed from the company, an ethics commi…
Matched conditions: CHRONIC GRAFT VS. HOST DISEASE
Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Researchers launch major study to unravel mysteries of chronic GVHD
Knowledge-focused Recruiting nowThis study follows 650 people with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. Researchers aim to track the disease over time, identify biological markers, and improve how it is diagnosed and managed. Participants undergo regular check-u…
Matched conditions: CHRONIC GRAFT VS. HOST DISEASE
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC